Aim: The aim of this study was to compare vascularity observed using contrast-enhanced 3D
ultrasonography and pathological changes in human hepatocellular carcinoma (HCC) and …

The present study aimed to determine the usefulness of contrast-enhanced ultrasonography
(CEUS) with Sonazoid in evaluating the therapeutic response to sorafenib for hepatocellular …

AIM: To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-
enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib …

Purpose: In order to detect an early response to anti-angiogenic therapy, this study aims at
analyzing specific effects of a sorafenib-based regime on intra-tumoral D-CEUS flow …

Objectives To compare the accuracy of contrast-enhanced ultrasound (CEUS) and Dynamic
contrast-enhanced (DCE) magnetic resonance imaging (MRI) for the assessment of …

Aims: To evaluate the sonographic changes observed in hepatocellular carcinoma (HCC)
post antiangiogenic treatment with sorafenib. Patients and methods: Twenty one …

Aim Early evaluation of the response to sorafenib for patients with hepatocellular carcinoma
(HCC) remains unclear. This prospective study investigated the early evaluation of the …

AIM: To verify whether arterial-phase contrast-enhanced ultrasonography (CEUS) of tumor
parenchymal tissue is useful for evaluation of anti-angiogenesis agents. METHODS: Rabbits …

Objective: This study evaluated the feasibility of CT perfusion parameters for the early
efficacy prediction of sorafenib in the treatment of hepatocellular carcinoma (HCC) in rats …

Background: Sorafenib is a multikinase inhibitor targeting Raf and protein tyrosine kinases,
which are involved in cell growth and tumor angiogenesis. Sorafenib administration induces …